Literature DB >> 16203795

Bladder cancer stage and outcome by array-based comparative genomic hybridization.

Ekaterini Blaveri1, Jeremy L Brewer, Ritu Roydasgupta, Jane Fridlyand, Sandy DeVries, Theresa Koppie, Sunanda Pejavar, Kshama Mehta, Peter Carroll, Jeff P Simko, Frederic M Waldman.   

Abstract

PURPOSE: Bladder carcinogenesis is believed to follow alternative pathways of disease progression driven by an accumulation of genetic alterations. The purpose of this study was to evaluate associations between measures of genomic instability and bladder cancer clinical phenotype. EXPERIMENTAL
DESIGN: Genome-wide copy number profiles were obtained for 98 bladder tumors of diverse stages (29 pT(a), 14 pT1, 55 pT(2-4)) and grades (21 low-grade and 8 high-grade superficial tumors) by array-based comparative genomic hybridization (CGH). Each array contained 2,464 bacterial artificial chromosome and P1 clones, providing an average resolution of 1.5 Mb across the genome. A total of 54 muscle-invasive cases had follow-up information available. Overall outcome analysis was done for patients with muscle-invasive tumors having "good" (alive >2 years) versus "bad" (dead in <2 years) prognosis.
RESULTS: Array CGH analysis showed significant increases in copy number alterations and genomic instability with increasing stage and with outcome. The fraction of genome altered (FGA) was significantly different between tumors of different stages (pT(a) versus pT1, P = 0.0003; pT(a) versus pT(2-4), P = 0.02; and pT1 versus pT(2-4), P = 0.03). Individual clones that differed significantly between different tumor stages were identified after adjustment for multiple comparisons (false discovery rate < 0.05). For muscle-invasive tumors, the FGA was associated with patient outcome (bad versus good prognosis patients, P = 0.002) and was identified as the only independent predictor of overall outcome based on a multivariate Cox proportional hazards method. Unsupervised hierarchical clustering separated "good" and "bad" prognosis muscle-invasive tumors into clusters that showed significant association with FGA and survival (Kaplan-Meier, P = 0.019). Supervised tumor classification (prediction analysis for microarrays) had a 71% classification success rate based on 102 unique clones.
CONCLUSIONS: Array-based CGH identified quantitative and qualitative differences in DNA copy number alterations at high resolution according to tumor stage and grade. Fraction genome altered was associated with worse outcome in muscle-invasive tumors, independent of other clinicopathologic parameters. Measures of genomic instability add independent power to outcome prediction of bladder tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203795     DOI: 10.1158/1078-0432.CCR-05-0177

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  58 in total

Review 1.  Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

Authors:  David D Chism; Michael E Woods; Matthew I Milowsky
Journal:  Oncologist       Date:  2013-07-24

2.  Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).

Authors:  Mark Jesus M Magbanua; Hope S Rugo; Denise M Wolf; Louai Hauranieh; Ritu Roy; Praveen Pendyala; Eduardo V Sosa; Janet H Scott; Jin Sun Lee; Brandelyn Pitcher; Terry Hyslop; William T Barry; Steven J Isakoff; Maura Dickler; Laura Van't Veer; John W Park
Journal:  Clin Cancer Res       Date:  2018-01-08       Impact factor: 12.531

Review 3.  Molecular biology of bladder cancer.

Authors:  William Martin-Doyle; David J Kwiatkowski
Journal:  Hematol Oncol Clin North Am       Date:  2015-01-31       Impact factor: 3.722

Review 4.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

5.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.

Authors:  Didier Jean; Emilie Thomas; Elodie Manié; Annie Renier; Aurélien de Reynies; Céline Lecomte; Pascal Andujar; Jocelyne Fleury-Feith; Françoise Galateau-Sallé; Marco Giovannini; Jessica Zucman-Rossi; Marc-Henri Stern; Marie-Claude Jaurand
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

6.  Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

Authors:  C D Hurst; D C Tomlinson; S V Williams; F M Platt; M A Knowles
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

7.  Classification of arrayCGH data using fused SVM.

Authors:  Franck Rapaport; Emmanuel Barillot; Jean-Philippe Vert
Journal:  Bioinformatics       Date:  2008-07-01       Impact factor: 6.937

8.  Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis.

Authors:  Eric Letouzé; Yves Allory; Marc A Bollet; François Radvanyi; Frédéric Guyon
Journal:  Genome Biol       Date:  2010-07-22       Impact factor: 13.583

9.  Determining frequent patterns of copy number alterations in cancer.

Authors:  Franck Rapaport; Christina Leslie
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

10.  Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer.

Authors:  Karsten Zieger; Carsten Wiuf; Klaus Møller-Ernst Jensen; Torben Falck Ørntoft; Lars Dyrskjøt
Journal:  BMC Cancer       Date:  2009-05-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.